Ranimustine

Ranimustine

Clinical data
Trade names	Cymerin
AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	L01AD07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name Methyl 6-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-6-deoxy-α-D-glucopyranoside
Synonyms	1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea
CAS Number	58994-96-0 Y
PubChem CID	71741
ChemSpider	64785
UNII	RYH2T97J77
Chemical and physical data
Formula	C10H18ClN3O7
Molar mass	327.71 g/mol
3D model (JSmol)	Interactive image
SMILES CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CNC(=O)N(CCCl)N=O)O)O)O
InChI InChI=1S/C10H18ClN3O7/c1-20-9-8(17)7(16)6(15)5(21-9)4-12-10(18)14(13-19)3-2-11/h5-9,15-17H,2-4H2,1H3,(H,12,18)/t5-,6-,7+,8-,9+/m1/s1 Key:AHHFEZNOXOZZQA-ZEBDFXRSSA-N

Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera.

It has never been filed for FDA evaluation in the United States, where it is not marketed.